Evidence map›Paper›PMID 2642759›Full record

Trial reportCirculation1989

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.

D J Gordon, J L Probstfield, R J Garrison, J D Neaton, W P Castelli, J D Knoke, D R Jacobs, S Bangdiwala, H A Tyroler

3 registry-linked trialsAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Circulation, 1989. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 795 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
795citing papers in PubMed, 13 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03906539 phase4completedstarted 2019, after this paper: background citation

Effect of Virgin Coconut Oil (VCO) on Cardiometabolic Parameters in Patients With Dyslipidemia: A Randomized, add-on, Placebo-controlled Clinical Trial

Ran2019Enrolled150Registered outcomes11Posted comparisons0ConditionsDyslipidemiasArmsAtorvastatin 10mg, Placebo, Virgin Coconut Oil (VCO)
PMID 15249516PMID 5787998PMID 15329324PMID 15364185PMID 17190864PMID 17635891PMID 17827859PMID 23305031PMID 24222016PMID 26545671PMID 28816548PMID 29079969other papers from this trial
Open the trial in the graph
NCT00005128 completednot on this map

Lipid Research Clinics Population Studies

TypeobservationalSponsorNational Heart, Lung, and Blood Institute (NHLBI)Ran1972 to 1994ConditionsCardiovascular Diseases, Atherosclerosis, Coronary Disease, Heart Diseases
NCT00552747 phase4completednot on this mapstarted 2007, after this paper: background citation

The Effect of Fenofibrate on Endothelial Function and HDL in Patients With Coronary Heart Disease and LDL-C at Goal

TypeinterventionalSponsorNational Heart Institute, MexicoRan2007 to 2011Enrolled76ConditionsCoronary Heart Disease, HyperlipidemiaArmsfenofibrate, placebo
3 · Its place in the literature

Who cites it

795 citing papers in PubMed, 13 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Guideline
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

735 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

D J GordonLipid Metabolism-Atherogenesis Branch, National Institutes of Health, Bethesda, Maryland, MD 20892.
J L Probstfield
R J Garrison
J D Neaton
W P Castelli
J D Knoke
D R Jacobs
S Bangdiwala
H A Tyroler

Funding

SUPPORT FOR LIPID RESEARCH CLINICN01HV012156 · HV · BAYLOR COLLEGE OF MEDICINE · PI INSULL, WILLIAM JR · 1985 to 1990
–
NHLBI NIH HHS N01-HV12156NHLBI NIH HHS N01-HV12159NHLBI NIH HHS N01-HV32961
6 · The paper itself

Abstract

The British Regional Heart Study (BRHS) reported in 1986 that much of the inverse relation of high-density lipoprotein cholesterol (HDLC) and incidence of coronary heart disease was eliminated by covariance adjustment. Using the proportional hazards model and adjusting for age, blood pressure, smoking, body mass index, and low-density lipoprotein cholesterol, we analyzed this relation separately in the Framingham Heart Study (FHS), Lipid Research Clinics Prevalence Mortality Follow-up Study (LRCF) and Coronary Primary Prevention Trial (CPPT), and Multiple Risk Factor Intervention Trial (MRFIT). In CPPT and MRFIT (both randomized trials in middle-age high-risk men), only the control groups were analyzed. A 1-mg/dl (0.026 mM) increment in HDLC was associated with a significant coronary heart disease risk decrement of 2% in men (FHS, CPPT, and MRFIT) and 3% in women (FHS). In LRCF, where only fatal outcomes were documented, a 1-mg/dl increment in HDLC was associated with significant 3.7% (men) and 4.7% (women) decrements in cardiovascular disease mortality rates. The 95% confidence intervals for these decrements in coronary heart and cardiovascular disease risk in the four studies overlapped considerably, and all contained the range 1.9-2.9%. HDLC levels were essentially unrelated to non-cardiovascular disease mortality. When differences in analytic methodology were eliminated, a consistent inverse relation of HDLC levels and coronary heart disease event rates was apparent in BRHS as well as in the four American studies.

Indexed as

AdultAgedCardiovascular DiseasesCholesterol, HDLClinical Trials as TopicCohort StudiesFemaleHumansMaleMiddle AgedProspective StudiesRegression AnalysisRisk FactorsSex FactorsStatistics as TopicCholesterol, HDL

Identifiers

PMID2642759

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.